We are thrilled to announce that Neuronostics has successfully raised $2 million in funding. Neuronostics is a groundbreaking company that is transforming the landscape of neurological condition diagnosis and treatment through innovative mathematical modeling techniques. Our flagship product, BioEP, is a cutting-edge digital biomarker for epilepsy that leverages EEG data and predictive algorithms to assess seizure risk. With this new funding, Neuronostics aims to further develop BioEP and expand its application to other neurological conditions, ultimately revolutionizing neurological healthcare globally. We are committed to creating a future where digital biomarkers are a routine part of neurology care, leading to more proactive and effective treatment for individuals living with neurological disorders.












